Dialogue and Diagnosis - American Osteopathic Association

Adding glucagon-like peptide-1
receptor agonists to insulin therapy
for patients with type 2 diabetes
mellitus: why and how?
James R. LaSalle, DO
L
ong standing diabetes creates special challenges
for the physician and patient. The progressive
pathophysiologic nature of diabetes mellitus
results in the need for numerous medications to
address multiple metabolic defects, 1 with an increasing
likelihood of the need for insulin as -cell function declines. 2
The necessary polypharmacy creates adherence and
tolerability challenges for patients. 3
Dialogue and Diagnosis // September 2012
23